Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Hydroxychloroquine in Advanced Pancreatic Cancer
NCT03825289Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Jan 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxychloroquine and trametinib in pancreatic cancer (PC), sponsored by University of Utah. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Jan 2019; status: terminated.
02
Drugs
hydroxychloroquinetrametinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03825289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825289.